 Home > Medical News > Medicines Company News > Pfizer acquires Amplyx to expand anti-infective drug R&D pipeline

Pfizer acquires Amplyx to expand anti-infective drug R&D pipeline

 Last Update: 2021-05-10
 Source: Internet
 Author: User

Tags

1 4 socket

fusarium infection

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On April 28, Pfizer announced that it had acquired Amplyx Pharmaceuticals (referred to as Amplyx).

Globally, infectious diseases cause more than 8.

Fosmanogepix has a novel mechanism of action and has the potential to target fungal strains resistant to standard treatments.

In addition to fosmanogepix, through this acquisition, Pfizer also acquired the ownership of Amplyx's early-stage pipeline, which includes potential antiviral (MAU868) and antifungal (APX2039) therapies.

Reference materials:

[1] Pfizer Acquires Amplyx Pharmaceuticals.

Reference materials:

[1] Pfizer Acquires Amplyx Pharmaceuticals.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.